Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. In the active-control study, recurrent ...

Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically ...

SILVER SPRING, MD (updated, corrected) — A massive study of Medicare patients at risk of stroke secondary to atrial fibrillation (AF) has found no signal of increased MI risk with dabigatran (Pradaxa, ...

What patient factors affect bleeding risk with dabigatran? Dabigatran may be similar to warfarin in terms of gastrointestinal bleeding risk in older adults. In a retrospective cohort study comparing ...

Ascend Laboratories, maker of generic dabigatran etexilate, is recalling 10 manufacturing lots of the oral anticoagulant because of an unacceptably high level of a possible carcinogen, according to a ...

Approximately 1 in 4 patients with nonvalvular atrial fibrillation (A-fib) who are prescribed dabigatran do not take it as directed and are therefore at increased risk for adverse clinical events, ...

The Appraisal Committee considered evidence submitted by the manufacturer of dabigatran etexilate for the prevention of venous thromboembolism (VTE) after hip or knee replacement surgery in adults and ...

Since July 1, 2011, the thrombin inhibitor dabigatran has been available in New Zealand for stroke prevention in patients with atrial fibrillation. There are no restrictions on prescribing, and access ...

Please provide your email address to receive an email when new articles are posted on . Dabigatran is an oral anticoagulant - a synthetic thrombin inhibitor – that is approved in the United States for ...

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dabigatran, having considered evidence on the nature of atrial fibrillation and the value placed on ...

Extended apixaban or dabigatran reduces recurrent VTE Extended anticoagulation with apixaban or dabigatran reduces recurrent VTE and mortality without increasing major bleeding. Level 1: Likely ...